publication date: Oct. 16, 2020

Trials & Tribulations

COVID and lung cancer: How experts in cancer and virology joined forces in a challenging time

Fred R. Hirsch

Fred R. Hirsch, MD, PhD

Executive director, Center for Thoracic Oncology,

Mount Sinai Cancer, Mount Sinai Health System;

Professor of medicine and pathology, Icahn School of Medicine;

Joe Lowe and Louis Price Professor of Medicine;

Associate director, Tisch Cancer Institute


This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. A full list of our coverage is available here.

Researchers from Icahn School of Medicine at Mount Sinai was recently awarded a U54 grant ($3.9 million over the first two years as a part of a five-year research proposal) to establish a NCI/SeroNet Center for Serological Excellence at Mount Sinai with a focus on lung cancer.

The Center of Excellence at Mount Sinai for lung cancer will be led by Fred R. Hirsch, MD, PhD, executive director for the Center for Thoracic Oncology at the Tisch Cancer Institute and professor of medicine and pathology at Icahn School of Medicine, and Professor Adolfo García-Sastre, PhD, an expert in virology at Icahn School of Medicine, Mount Sinai.

From different registries throughout the world, it was clearly demonstrated that patients with lung cancer, who contracted infection with SARS-CoV-2 virus, and particularly those who were hospitalized for COVID-19, had a very aggressive course of the COVID-19, leading to a high mortality rate due to COVID-19.

Continue reading COVID and lung cancer: How experts in cancer and virology joined forces in a challenging time
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.